
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is a technology company with a positive outlook, as evidenced by the recent Los Reyes PEA, which outlines a NPV of US$1,491M, IRR of 37.3%, and payback of 1.9 years on upfront capital of US$515M. The company anticipates LOM production to average 134 koz AuEq per year over 14.4 years, with a significant increase in the first 11 years and a low LOM AISC of US$1,617/oz AuEq. Furthermore, the company has a strong financial outlook, with plans for internal funding from Morelos FCF for future growth and a conference call scheduled to discuss the positive PEA results.
Bears say
10x Genomics is currently facing challenges in terms of its valuation and financials, with a current valuation at 7.7x 2028 estimated enterprise value/revenue and a price-to-naval value of 0.51x. Additionally, the company has incurred significant debt of $84 million, further impacting its outlook. These factors, coupled with the company's reliance on development-stage assets, contribute to a negative outlook on its stock.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares